Health status and costs of exacerbations of chronic bronchitis and COPD: How to improve antibiotic treatment

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 5, Issue 4, 2005, Pages 423-435

  Miravitlles, Marc ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Antibiotics; Chronic bronchitis; Chronic obstructive pulmonary disease; Costs; Exacerbations; Failure; Health status; Treatment

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; BRONCHODILATING AGENT; CEFUROXIME; CEPHALOSPORIN; CLARITHROMYCIN; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; GEMIFLOXACIN; MACROLIDE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE;

CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OBSERVATION; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; ECONOMIC EVALUATION; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEALTH STATUS; HUMAN; LONGITUDINAL STUDY; MORBIDITY; MORTALITY; POPULATION RESEARCH; PREDICTION; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; SELF REPORT; SURVIVAL RATE; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 24744446265     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.5.4.423     Document Type: Review

References (89)

1. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 23, 932-946 (2004).
2. Mannino DM, Brown C, Giovino GA. Obstructive lung disease deaths in the United States from 1979 through 1993. An analysis using multiple-cause mortality data. Am. J. Respir. Crit. Care Med. 156, 814-818 (1997).
3. Sobradillo, V, Miravitlles M, Gabriel R et al. Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest 118, 981-989 (2000).
4. Jiménez-Ruiz CA, Masa F, Miravitlles M et al. Smoking characteristics: attitudes and dependence. Differences between healthy smokers and smokers with COPD. Chest 119, 1365-1370 (2001).
5. Cerveri I, Accordini S, Verlato G et al. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur. Respir. J. 18, 85-92 (2001).
6. Feenstra TL, van Genugten MLL, Hoogenveen RT, Wouters EF, Rutten van Mölken MPMH. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164, 590-596 (2001).
7. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 157, 1418-1422 (1998).
8. Miravitlles M, Ferrer M, Pont A et al. Exacerbations impair quality of life in patients with chronic obstructive pulmonary disease. A two-year follow-up study. Thorax 59, 387-395 (2004).
9. Burrows B, Bloom JW, Traver GA, Cline MG. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N. Engl. J. Med. 317, 1309-1314 (1987).
10. Ball P, Harris JM, Lowson D, Tillotson G, Wilson R. Acute infective exacerbations of chronic bronchitis. QJM 88, 61-68 (1995).
11. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in out-patients with acute exacerbations of COPD. Chest 117, 1345-1352 (2000).
12. Miravitlles M, Murio C, Guerrero T on Behalf of the DAFNE Study Group. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. A prospective multicenter study in the community. Eur. Respir. J. 17, 928-933 (2001).
13. Traver GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study. Am. Rev. Respir. Dis. 119, 895-902 (1979).
14. Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnea, and excercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 350, 1005-1012 (2004).
15. Engström CP, Persson LO, Larsson S, Sullivan M. Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur. Respir. J. 18, 69-76 (2001).
16. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 56, 880-887 (2001).
17. Doll H, Miravitlles M. Quality of life in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: a review of the literature. Pharmacoeconomics 23, 345-363 (2005).
18. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. Am. Rev. Respir. Dis. 145, 1321-1327 (1992).
19. Guyatt GH, Berman LB, Towsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 42, 773-778 (1987).
20. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J. Clin. Epidemiol. 47, 81-87 (1994).
21. Doll H, Grey-Amante P, Duprat-Lomon I et al. Quality of life in acute exacerbations of chronic bronchitis: results from a German population study. Respir. Med. 96, 39-51 (2002).
22. Doll H, Duprat-Lomon I, Ammerman E, Sagnier PP. Validity of the St George's respiratory questionnaire at acute exacerbation of chronic bronchitis: comparison with the Nottingham health profile. Qual. Life Res. 12, 117-132 (2003).
23. Grossman R, Mukherjee J, Vaughan D et al. A 1 -year community-based health economic study of ciprofloxacin vs. usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 113, 131-141 (1998).
24. Miravitlles M. Designing future clinical trials for acute exacerbations of chronic bronchitis. In: Mechanisms and Management of COPD Exacerbations. Allegra L, Blasi F (Eds). Springer-Verlag, Milan, Italy, 88-99 (2000).
25. Aaron SD, Vandemheen KL, Clinch JJ et al. Measurment of short-term changes in dyspnoea and disease-specific quality of life following an acute COPD exacerbation. Chest 121, 688-696 (2002).
26. Aaron SD, Vandemheen KL, Hebert N et al. Out-patient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N. Engl. J. Med. 348, 2618-2625 (2003).
27. Spencer S, Jones PW for the GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 58, 589-593 (2003).
28. Andersson I, Johansson K, Larsson S, Pehrsson K. Long-term oxygen therapy and quality of life in elderly patients hospitalised due to severe exacerbation of COPD. A 1 year follow-up study. Respir. Med. 96, 944-949 (2002).
29. Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 161, 1608-1613 (2000).
30. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur. Respir. J. 19, 398-404 (2002).
31. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following six months treatment with once daily tiotropium compared to twice daily salmeterol in patients with COPD. Thorax 58, 399-404 (2003).
32. Spencer S, Calverley PMA, Burge PS, Jones PW on behalf of the ISOLDE Study Group. Health status deterioration in patients with chronic obstructive pulmonay disease. Am. J. Respir. Crit. Care Med. 163, 122-128 (2001).
33. Oga T, Nishimura K, Tsukino M et al. Longitudinal changes in health status using the Chronic Respiratory Disease Questionnaire and pulmonary function in patients with stable chronic obstructive pulmonary disease. Qual. Life Res. 13, 1109-1116 (2004).
34. Osman LM, Godden DJ, Friend JAR, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 52, 67-71 (1997).
35. Tu SP, McDonell MB, Spertus JA et al. A new self-administered questionnaire to monitor health-related quality of life in patients with COPD: Ambulatory Care Quality Improvement Project (ACQUIP) Investigators. Chest 112, 614-622 (1997).
36. Fan VS, Curtis JR, Tu SP, McDonell MB, Fihn SD for the Ambulatory Care Quality Improvement Project Investigators. Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases. Chest 122, 429-436 (2002).
37. Domingo-Salvany A, Lamarca R, Ferrer M et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 166, 680-685 (2002).
38. Oga T, Nishimura K, Tsukino M et al. Health status measured with the CRQ does not predict mortality in COPD. Eur. Respir. J. 20, 1147-1151 (2002).
39. Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320, 1297-1303 (2000).
40. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 351, 773-780 (1998).
41. Miravitlles M, Mayordomo C, Artés M, Sánchez-Agudo L, Nicolau F, Segú JL on Behalf of the EOLO Group. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. Respir. Med. 93, 173-179 (1999).
42. Fuso L, Incalzi RA, Pistelli R et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am. J. Med. 98, 272-277 (1995).
43. Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbations of chronic obstructive pulmonary disease. JAMA 274, 1852-1857 (1995).
44. Vilkman S, Keistinen T, Tuuponen T, Kivelä SL. Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. Respiration 64, 281-284 (1997).
45. Vestbo J, Prescott E, Lange P, Schnohr P, Jensen G. Vital prognosis after hospitalization for COPD: a study of a random population sample. Respir Med. 92, 772-776 (1998).
46. Connors Jr AF, Dawson NV, Thomas C et al. Outcomes following acute exacerbation of severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 154, 959-967 (1996).
47. Miravitlles M, Guerrero T, Mayordomo C, Sánchez-Agudo L, Nicolau F, Segú JL on Behalf of the EOLO Group. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respiration 67, 495-501 (2000).
48. Antonelli Incalzi R, Fuso L, De Rosa M et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur. Respir. J. 10, 2794-2800 (1997).
49. Loukides S, Polyzogopoulos D. The effect of diabetes mellitus on the outcome of patients with chronic obstructive pulmonary disease exacerbated due to respiratory infections. Respiration 63, 170-173 (1996).
50. Ferrer M, Alonso J, Morera J et al. Chronic obstructive pulmonary disease stage and health-related quality of life. Ann. Intern. Med. 127, 1072-1079 (1997).
51. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur. Respir. J. 8, 1333-1338 (1995).
52. Lange R Nyboe J, Appleyard M, Jensen G, Schnohr P. Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax 45, 579-585 (1990).
53. Hansen EF, Phanareth K, Laursen LC, Kok-Jensen A, Dirksen A. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 159, 1267-1271 (1999).
54. Miravitlles M, Espinosa C, Fernández-Laso E et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 116, 40-46 (1999).
55. DeAbate CA, Henry D, Bensch G et al. Sparfloxacin vs. ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis. A multicenter, double-blind, randomized, comparative study. Chest 114, 120-130 (1998).
56. Chodosh S, DeAbate CA, Haverstock D, Aneiro L, Church D, The Bronchitis Study Group. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Respir. Med. 94, 18-27 (2000).
57. Sachs APE, Köter GH, Groenier KH, van der Waaij D, Schiphuis J, Meyboom-de Jong B. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 50, 758-763 (1995).
58. Macfarlane J, Holmes W, Gard P et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax 56, 109-114 (2001).
59. Murata GH, Gorby MS, Kapsner CO, Chick TW, Halperin AK. A multivariate model for predicting hospital admissions for patients with decompensated chronic obstructive pulmonary disease. Arch. Intern. Med. 152, 82-86 (1992).
60. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 106, 196-204 (1987).
61. Hilleman DE, Dewan N, Malesker M et al. Pharmacoeconomic evaluation of COPD. Chest 118, 1278-1285 (2000).
62. Jacobson L, Hertzman P, Löfdahl CG et al. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Respir. Med. 94, 247-255 (2000).
63. Wilson L, Devine EB, So K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir. Med. 94, 204-213 (2000).
64. Miravitlles M, Murio C, Guerrero T, Gisbert R on behalf of the DAFNE study group. Costs of chronic bronchitis and COPD. A one year follow-up study. Chest 123, 784-791 (2003).
65. Masa JF, Sobradillo V, Villasante C et al. Costs of chronic obstructive pulmonary disease in Spain: estimation from a population-based study. Arch. Bronconeumol. 40, 72-79 (2004).
66. Oostenbrink JB, Rutten-van Mölken MPMH. Resource use and risk factors in high-cost exacerbations of COPD. Respir. Med. 98, 883-891 (2004).
67. Andersson F, Borg S, Jansson S-A et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir. Med. 96, 700-708 (2002).
68. Izquierdo-Alonso JL, de Miguel-Díez J. Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease. COPD 1, 215-223 (2004).
69. Miravitlles M, Murio C, Guerrero T, Gisbert R on behalf of the DAFNE study group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 121, 1449-1455 (2002).
70. García-Aymerich J, Barreiro E, Farrero E, Marrades RM, Morera J, Antó JM. Patients hospitalized for COPD have a high prevalence of modifiable risk factors for exacerbation (EFRAM study). Eur. Respir. J. 16, 1037-1042 (2000).
71. Drummond MF, Becker DL, Hux M et al. An economic evaluation of sequential IV/po moxifloxacin therapy compared to IV/po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 124, 526-535 (2003).
72. Dewan NA, Rafique S, Kanwar B et al. Acute exacerbations of COPD. Factors associated with poor treatment outcome. Chest 117, 662-671 (2000).
73. Davey PG. Cost management in community-acquired lower respiratory tract infection. Am. J. Med. 99(Suppl. 6B), S20-S23 (1995).
74. Evans AT, Husain S, Durairaj L, Sadowski LS, Charles-Damte M, Wang Y. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet 359, 1648-1654 (2002).
75. Bjerrum L, Boada A, Cots JM et al. Respiratory tract infections in general practice: considerable differences in prescribing habits between general practitioners in Denmark and Spain. Eur. J. Clin. Pharmacol. 60, 23-28 (2004).
76. Allegra L, Grassi C, Grossi E et al. Ruolo degli antibiotici nel trattamento delle riacutizzazioni della bronchite cronica: risultati di uno studio italiano multicentrico. Ital. J. Chest Dis. 45, 138-148 (1991).
77. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-ananlysis. JAMA 273, 957-960 (1995).
78. Miravitlles M, Torres A. No more equivalence trials for antibiotics in exacerbations of COPD, please. Chest 125, 811-813 (2004).
79. Miravitlles M, Zalacain R, Murio C et al. Speed of recovery from acute exacerbations of COPD after treatment with antimicrobials: results of a two-year study. Clin. Drug Invest. 23, 439-450 (2003).
80. Llor C, Naberan K, Cots JM, Molina J, Miravitlles M. Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care centers. Int. J. Clin. Pract. 58, 937-944 (2004).
81. Balter MS, La Forge J, Low DE, Mandell L, Grossman RF. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can. Respir. J. 10(Suppl. B), 3B-32B (2003).
82. ALAT Work Group. Update to the Latin American Thoracic Society (ALAT) recommendations on infectious exacerbation of COPD. Arch. Bronconeumol. 40, 315-325 (2004).
83. Anzueto A, Rizzo JA, Grossman RF. The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbation of chronic bronchitis. Clin. Infect. Dis. 28, 1344-1345 (1999).
84. Wilson R, Schentag JJ, Ball P, Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin. Ther. 24, 639-652 (2002).
85. Wilson R, Allegra L, Huchon G et al. Short and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 125, 953-964 (2004).
86. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and out-patient management of acute exacerbations of COPD. Chest 117, 1638-1645 (2000).
87. Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 57, 759-764 (2002).
88. Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur. Respir. J. 20(Suppl. 36), S9-S19 (2002).
89. Soler JJ, Sánchez L, Román P, Martínez MA, Perpiñá M. Risk factors of emergency care and admissions in COPD patients with high consumption of health resources. Respir. Med. 98, 318-329 (2004).